Results 151 to 160 of about 64,832 (295)
Cancer Medicine, Volume 14, Issue 21, November 2025.ABSTRACT Purpose Programmed cell death protein 1 (PD‐1) inhibitor monotherapy is the standard second‐line treatment for esophageal squamous cell carcinoma (ESCC), but the clinical response and survival outcomes still remain unsatisfactory. This systematic review aims to assess the efficacy and safety of combined immunotherapy strategies in previously ...
Yong Chen +10 more
wiley +1 more source
Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]
, 2020 Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth +2 more
core
Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients
Cancer Medicine, Volume 14, Issue 21, November 2025.ABSTRACT Introduction Cancer patients are increasingly turning to cannabis products to modulate physical and psychological symptoms despite limited evidence supporting their efficacy. We aimed to explore cancer patients' self‐reported anxiety and depression symptoms in response to cannabis use.
Apoorva C. Reddy +7 more
wiley +1 more source
World Journal of Acupuncture - MoxibustionObjective: To summarize and analyze the recommendations of acupuncture and moxibustion in the global guidelines/expert consensus of chemotherapy- and/or radiotherapy-induced nausea and/or vomiting, providing a basis for the development of clinical ...
Tian-yu MING +10 more
doaj +1 more source
Cancer Medicine, Volume 14, Issue 21, November 2025.ABSTRACT Background Fruquintinib is a highly selective small‐molecule inhibitor that targets vascular endothelial growth factor receptors and is approved for the treatment of metastatic colorectal cancer. Given its increasing clinical adoption, a comprehensive pharmacovigilance evaluation of the adverse events (AEs) is warranted.
Yajing Xu, Dongchen Wang, Yuyan Xu
wiley +1 more source
Investigating chemotherapy adverse events : incidence, costs and consequences [PDF]
, 2013 University of Technology Sydney. Faculty of Business.Background: In Australia, economic evaluation is an important tool in prioritising healthcare spending.
Pearce, AM
core
Clinical Case Reports, Volume 13, Issue 11, November 2025.ABSTRACT Burkitt lymphoma is an aggressive non‐Hodgkin lymphoma. While kidney infiltration is well documented, acute kidney injury is an unusual presentation. Facial nerve palsy is even rarer. Here, we report a case of a 2‐year‐old boy with both of these unusual findings. He presented with acute kidney injury and bilateral nephromegaly. Two days later,
Gana Odeh +3 more
wiley +1 more source
Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
Cancer Management and Research, 2016 Megan Brafford May,1 Ashley E Glode2 1Department of Pharmacy, Baptist Health Lexington, Lexington, KY, USA; 2Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus ...
May MB, Glode AE
doaj
Cancer Reports, Volume 8, Issue 11, November 2025.ABSTRACT Introduction Internet‐based interventions have become a necessity in providing care. To assess quality‐of‐life perceptions among women living with breast cancer (BC) receiving any type of internet‐based treatments. Methods The present systematic review and meta‐analysis were registered in PROSPERO with the ID no. CRD42024498834.
Elsa Vitale +6 more
wiley +1 more source
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. [PDF]
, 2000 A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse.
Albright, RE +21 more
core